Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 267

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

Open access
Press, Oliver W., Li, Hongli, Schöder, Heiko, Straus, David J., Moskowitz, Craig H., LeBlanc, Michael, Rimsza, Lisa M., Bartlett, Nancy L., Evens, Andrew M., Mittra, Erik S., LaCasce, Ann S., Sweetenham, John W., Barr, Paul M., Fanale, Michelle A., Knopp, Michael V., Noy, Ariela, Hsi, Eric D., Cook, James R., Lechowicz, Mary Jo, Gascoyne, Randy D., Leonard, John P., Kahl, Brad S., Cheson, Bruce D., Fisher, Richard I., Friedberg, Jonathan W. · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. Patients and Methods: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012. A PET scan was performed after two initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2. PET2-negative patients (Deauville score 1 to 3) received an additional four cycles of ABVD, whereas PET2-positive patients (Deauville score 4 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles. Among 336 eligible and evaluable patients, the median age was 32 years (range, 18 to 60 years), with 52% stage III, 48% stage IV, 49% International Prognostic Score 0 to 2, and 51% score 3 to 7. Results: Three hundred thirty-six of the enrolled patients were evaluable. Central review of the interim PET2 scan was performed in 331 evaluable patients, with 271 (82%) PET2-negative and 60 (18%) PET2-positive. Of 60 eligible PET2-positive patients, 49 switched to eBEACOPP as planned and 11 declined. With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98% (95% CI, 95% to 99%), and the 2-year estimate for progression-free survival (PFS) was 79% (95% CI, 74% to 83%). The 2-year estimate for PFS in the subset of patients who were PET2-positive after two cycles of ABVD was 64% (95% CI, 50% to 75%). Both nonhematologic and hematologic toxicities were greater in the eBEACOPP arm than in the continued ABVD arm. Conclusion: Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.1119

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 267

Metadata

Authors
Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., LaCasce, A. S., Sweetenham, J. W., Barr, P. M., Fanale, M. A., Knopp, M. V., Noy, A., Hsi, E. D., Cook, J. R., Lechowicz, M. J., Gascoyne, R. D., Leonard, J. P., Kahl, B. S., Cheson, B. D., Fisher, R. I., & Friedberg, J. W.
Venue
Journal of Clinical Oncology
Published
2016-06-10
Volume
34
Issue
17
Pages
2020-2027
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2340968189
Cited by
267
References
24
FWCI
35.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816. https://app.cochat.ai/papers/10.1200/jco.2015.63.1119
The paper
Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., LaCasce, A. S., Sweetenham, J. W., Barr, P. M., Fanale, M. A., Knopp, M. V., Noy, A., Hsi, E. D., Cook, J. R., Lechowicz, M. J., . . . Friedberg, J. W. (2016). US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.1119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.